

In the Claims:

Please cancel claims 4 and 39-56 without prejudice or disclaimer to the subject matter claimed therein, and amend claims 1-3, 5, 15-17, 23-26, 31-33, 35, and 37 as follows, in accordance with the revised requirements of 37 C.F.R. § 1.121:

1. (Currently amended) An isolated nucleic acid comprising a polynucleotide having at least ~~20~~ 300 consecutive nucleotides of the nucleotide sequence SEQ ID No. 1, or an isolated nucleic acid of complementary sequence.

2. (Currently amended) The isolated nucleic acid according to claim 1, comprising a polynucleotide ~~which has at least 20 consecutive nucleotides~~ of the sequence SEQ ID No. 2, or an isolated nucleic acid of complementary sequence.

3. (Currently amended) The isolated nucleic acid according to claim 1, comprising a polynucleotide which has at least ~~20~~ 30 consecutive nucleotides of the sequence SEQ ID No. 3, or an isolated nucleic acid of complementary sequence.

4. (Canceled)

5. (Currently amended) The isolated nucleic acid according to claim 1, comprising a polynucleotide which has at least ~~20~~ 30 consecutive nucleotides of the sequence SEQ ID No. 5, or an isolated nucleic acid of complementary sequence.

6. (Original) The isolated nucleic acid according to claim 1, wherein said nucleic acid modifies the transcription of a polynucleotide placed under its control.

7. (Original) The isolated nucleic acid according to claim 6, wherein said isolated nucleic acid is a polynucleotide comprising a sequence ranging from the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

nucleotide at position -1 to the nucleotide at position -200, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

8. (Original) The isolated nucleic acid according to claim 6, wherein said isolated nucleic acid is a polynucleotide comprising a sequence ranging from the nucleotide at position -1 to the nucleotide at position -300, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

9. (Original) The isolated nucleic acid according to claim 6, comprising a polynucleotide ranging from the nucleotide at position -1 to the nucleotide at position -600, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

10. (Original) The isolated nucleic acid according to claim 6, comprising a polynucleotide ranging from the nucleotide at position -1 to the nucleotide at position -2894, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

11. (Original) The isolated nucleic acid according to claim 6, comprising a polynucleotide ranging from the nucleotide at position +120 to the nucleotide at position -995, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

12. (Original) The isolated nucleic acid according to claim 6, comprising a polynucleotide ranging from the nucleotide at position +108 to the nucleotide at

AI
cont

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

position -2228, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

13. (Original) The isolated nucleic acid according to claim 6, wherein said isolated nucleic acid activates the transcription of a polynucleotide of interest placed under its control.

14. (Original) The isolated nucleic acid according to claim 6, wherein said isolated nucleic acid inhibits the transcription of a polynucleotide of interest placed under its control.

15. (Currently amended) An isolated nucleic acid having at least 80% nucleotide identity with ~~an~~ the isolated nucleic acid according to claim 1.

16. (Currently amended) The isolated nucleic acid according to claim 15, wherein said isolated nucleic acid according to claim 15 modifies the transcription of a polynucleotide placed under its control.

17. (Currently amended) The isolated nucleic acid according to claim 15, wherein said isolated nucleic acid according to claim 15 is a polynucleotide comprising a sequence ranging from the nucleotide at position -1 to the nucleotide at position -300, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

18. (Original) The isolated nucleic acid according to claim 15, comprising a polynucleotide ranging from the nucleotide at position -1 to the nucleotide at

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

position -600, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

19. (Original) The isolated nucleic acid according to claim 15, comprising a polynucleotide ranging from the nucleotide at position -1 to the nucleotide at position -200, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

20. (Original) The isolated nucleic acid according to claim 15, comprising a polynucleotide ranging from the nucleotide at position -1 to the nucleotide at position -2894, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

21. (Original) The isolated nucleic acid according to claim 15, comprising a polynucleotide ranging from the nucleotide at position +120 to the nucleotide at position -995, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

22. (Original) The isolated nucleic acid according to claim 15, comprising a polynucleotide ranging from the nucleotide at position +108 to the nucleotide at position -2228, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

23. (Currently amended) An isolated nucleic acid which hybridizes, under high stringency hybridization conditions, with ~~an~~ the isolated nucleic acid according to claim 1.

24. (Currently amended) The isolated nucleic acid according to claim 23, wherein said isolated nucleic acid according to claim 23 modifies the transcription of a polynucleotide placed under its control.

25. (Currently amended) The isolated nucleic acid according to claim 24, wherein said isolated nucleic acid according to claim 24 is a polynucleotide comprising a sequence ranging from the nucleotide at position -1 to the nucleotide at position -300, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

26. (Currently amended) The isolated nucleic acid according to claim 24, wherein said isolated nucleic acid according to claim 24 is a polynucleotide comprising a sequence ranging from the nucleotide at position -1 to the nucleotide at position -200, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

27. (Original) The isolated nucleic acid according to claim 24, comprising a polynucleotide ranging from the nucleotide at position -1 to the nucleotide at position -600, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

28. (Original) The isolated nucleic acid according to claim 24, comprising a polynucleotide ranging from the nucleotide at position -1 to the nucleotide at

position -2894, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

29. (Original) The isolated nucleic acid according to claim 24, comprising a polynucleotide ranging from the nucleotide at position +120 to the nucleotide at position -995, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

30. (Original) The isolated nucleic acid according to claim 24, comprising a polynucleotide ranging from the nucleotide at position +108 to the nucleotide at position -2228, with respect to the first nucleotide transcribed, which is located at position 2894 of the nucleotide sequence SEQ ID No. 1.

AI
cont
31. (Currently amended) The isolated nucleic acid according to claim 24, wherein said isolated nucleic acid according to claim 24 activates the transcription of a polynucleotide of interest placed under its control.

32. (Currently amended) The isolated nucleic acid according to claim 24, wherein said isolated nucleic acid according to claim 24 inhibits the transcription of a polynucleotide of interest placed under its control.

33. (Currently amended) An isolated nucleic acid comprising the isolated nucleic acid according to ~~one of claims 1 to 32~~ claim 1, further comprising a polynucleotide encoding at least one compound chosen from polypeptides of interest and nucleic acids of interest.

34. (Original) The isolated nucleic acid according to claim 33, wherein said polynucleotide encoding at least one compound encodes at least one nucleic acid of interest chosen from sense oligonucleotides and antisense oligonucleotides.

35. (Currently amended) A recombinant vector comprising at least one isolated nucleic acid according to ~~one of claims 1 to 34~~ claim 1.

36. (Original) The recombinant vector according to claim 35, wherein said vector is chosen from a recombinant cloning vector and a recombinant expression vector.

37. (Currently amended) A host cell transformed with at least one isolated nucleic acid according to ~~one of claims 1 to 34~~ claim 1.

38. (Original) A host cell transformed with a recombinant vector according to claim 35.

Claims 39-56 (Canceled)

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com